Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
Recruiting · NCT06505018 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Cureety techcare
What this trial is about
The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy. The main questions it aims to answer are: * Is patient quality of life improved by using the telemonitoring platform? * Are patients hospitalized less frequently when using the telemonitoring platform? * Is the patient overall survival improved by telemonitoring ? Researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care. Participants using telemonitoring will answer questions about their symptoms on the platform. The platform will analyze these symptoms, assess the patient's general condition and provide advice accordingly. Medical staff will also access the platform to monitor the patient's general condition and contact them if necessary.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Signed a written informed consent form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients
- Patients ≥18 years of age.
- Patient with histologically documented metastatic triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) \<10%, Her2 negative status).
- Life expectancy \> 6 months as per investigator estimate.
- Patient initiating a marketed authorized first-line systemic treatment in the metastatic setting.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
- Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 of EORTC QLQ-C30 at baseline are mandatory)
- Affiliated to the social security system or equivalent health insurance.
- Patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines)
- Patient has access to a computer, tablet, or smartphone connected to the Internet.
Exclusion criteria
- Participation in another clinical trial using telemonitoring.
- Physical or psychological incapacity of the patient to use the digital telemonitoring Cureety Techcare, according to the investigator's discretion.
- Patient deprived of their liberty or under protective custody or guardianship.
Where it is running
51 locations listed.
- Institut de Cancérologie des Hauts-de-France (ICHF) - Arras, France
- Centre Hospitalier d'Auxerre - Auxerre, France
- Sainte Catherine - Institut du Cancer Avignon Provence - Avignon, France
- CH Aunay-Bayeux - Bayeux, France
- Centre Hospitalier Simone Veil de Beauvais - Beauvais, France
- ICHF - Centre Pierre Curie - Beuvry, France
- Hôpital Simone Veil de Blois - Blois, France
- Polyclinique bordeaux nord - Bordeaux, France
- Centre Hospitalier Fleyriat - Bourg-en-Bresse, France
- Centre de Cancérologie Privé de Caen Maurice Tubiana - Caen, France
- Centre Francois Baclesse - Caen, France
- Centre hospitalier de Carcasonne - Carcassonne, France
- Recherche Oncologie Clinqiue 37 (ROC 37) - Chambray-lès-Tours, France
- CH de Cholet - Cholet, France
- CH Colmar - Colmar, France
- Groupe Hospitalier Public du Sud de l'Oise (GHPSO) - Creil, France
- Centre Georges François Leclerc - Dijon, France
- Institut Andrée Dutreix - Dunkirk, France
- Centre Hospitalier Intercommunal de Fréjus Saint Raphael - Fréjus, France
- Groupe Hospitalier Mutualiste de Grenoble - Grenoble, France
- Groupe Hospitalier de La Rochelle-Ré-Aunis - La Rochelle, France
- CHU de la réunion - La Réunion, France
- Clinique Sainte Clotilde - La Réunion, France
- CHU Grenoble Alpes - La Tronche, France
- Centre Hospitalier Louis Pasteur - Le Coudray, France
- Centre Hospitalier Le Mans - Le Mans, France
- Centre Hospitalier Emile Roux - Le Puy-en-Velay, France
- GHBS Lorient - Lorient, France
- Centre Leon Berard - Lyon, France
- Clinique de la Sauvegarde - Lyon, France
- Hôpital Privé Jean Mermoz - Lyon, France
- Institut Paoli Calmettes - Marseille, France
- CHI de Mont-de-Marsan et du Pays des Sources - Mont-de-Marsan, France
- Centre de Cancérologie du Grand Montpellier - Montpellier, France
- Hôpital Privé du Confluent - Nantes, France
- Clinique Ambroise-Pare Hartmann - Neuilly-sur-Seine, France
- Hôpital Américain de PARIS - Neuilly-sur-Seine, France
- CHU de Nimes - Nîmes, France
- CHR Orleans - Orléans, France
- CHP Sainte-Marie - Osny, France
- Diaconesses Croix Saint-Simon Hospital Complex - Paris, France
- Centre hospitalier de Pau - Pau, France
- CARIO - Hopital Privé des Cotes d'Armor - Plérin, France
- CHU de Poitiers - Poitiers, France
- Institut Godinot - Reims, France
- Clinique Mathilde - Les Hôpitaux Privés Rouennais - Rouen, France
- CHU de Saint-Etienne - Saint-Etienne, France
- Hia Begin - Saint-Mandé, France
- CHU de Tours - Tours, France
- Institut de Cancérologie de Lorraine - Vandœuvre-lès-Nancy, France
- CH Annecy Genevois - Épagny, France